Reagents for Adenovirus Assay DevelopmentInquiry Basket
Loading ......
Adenoviruses are non-enveloped, double-stranded DNA viruses belonging to the family Adenoviridae. Human adenoviruses are widely distributed pathogens associated with a variety of diseases, including respiratory infections, conjunctivitis, gastrointestinal disorders, and severe infections in immunocompromised individuals.
Although most adenovirus infections are self-limiting, certain adenovirus serotypes can cause significant outbreaks, particularly in closed or high-density populations. The development of adenovirus vaccines has therefore been an important strategy for preventing adenovirus-associated diseases.
Adenovirus vaccine research includes two major areas. The first involves vaccines designed specifically to prevent infection caused by human adenoviruses, primarily targeting adenovirus serotypes associated with respiratory disease. The second focuses on recombinant adenovirus vector vaccines, where engineered adenoviruses are used as delivery platforms to express antigens from other pathogens or tumor-associated targets. With their strong immunogenicity, flexible genetic engineering properties, and ability to induce both antibody and cellular immune responses, adenoviruses have become important tools in modern vaccine development.
Vaccines designed to prevent adenovirus infection aim to generate protective immunity against specific human adenovirus serotypes.
Currently, the most established adenovirus vaccines are live attenuated oral vaccines targeting adenovirus type 4 (Ad4) and adenovirus type 7 (Ad7), which are major causes of adenovirus-associated respiratory disease.
These vaccines contain weakened adenovirus strains that retain immunogenicity while reducing pathogenic potential. Following oral administration, attenuated viruses stimulate immune responses that protect against subsequent adenovirus exposure. Ad4 and Ad7 vaccines have been particularly valuable in populations with increased adenovirus transmission risk, including military personnel and individuals living in close-contact environments.
| Feature | Description |
| Vaccine type | Live attenuated adenovirus vaccine |
| Target serotypes | Adenovirus type 4 and type 7 |
| Administration route | Oral |
| Main purpose | Prevention of adenovirus respiratory infection |
| Immune protection | Neutralizing antibodies and mucosal immunity |
Protection against adenovirus infection is primarily mediated by antibodies targeting viral surface proteins, including hexon and fiber proteins. These antibodies can interfere with viral attachment and entry into host cells, reducing infection and disease severity.
In addition to preventing adenovirus infections, adenoviruses have been widely developed as vaccine delivery platforms. Recombinant adenovirus vector vaccines use genetically modified adenoviruses to deliver genes encoding protective antigens from unrelated pathogens. After vaccination, host cells express the encoded antigen, stimulating antigen-specific immune responses.
Common adenovirus vector platforms include:
These platforms have been extensively studied due to their ability to induce strong humoral and cellular immunity.
Compared with traditional protein-based vaccines, adenovirus vectors can efficiently activate antigen presentation pathways, leading to robust CD8+ T-cell responses in addition to antibody production.
Fig. 1 Mechanism of Adenovirus vector-based vaccine for COVID-19
Successful adenovirus vaccine development requires careful selection of viral targets, antigen design, and vector optimization.
The adenovirus capsid consists mainly of hexon, penton base, and fiber proteins, which play important roles in viral structure, host interaction, and immune recognition.
Hexon is the most abundant adenovirus capsid protein and contains major antigenic regions recognized by host antibodies. Because of its conserved immunogenic properties, hexon is frequently used as a target for adenovirus detection, antibody development, and serological studies.
The fiber protein mediates adenovirus attachment to host cell receptors and contributes to differences in tissue tropism among adenovirus serotypes. Modifying fiber regions is an important strategy for improving adenovirus vector targeting and vaccine performance.
Fig. 2 Adenovirus 3D structure
For recombinant adenovirus vaccines, genetic engineering approaches are used to:
Vector selection is also critical because pre-existing immunity against certain adenovirus serotypes may influence vaccine performance.
Evaluation of immune responses is an essential component of adenovirus vaccine development. Adenovirus vaccines can induce both antibody-mediated and cellular immune responses.
Neutralizing antibodies generated after vaccination can prevent viral infection by blocking viral attachment and entry.
Common approaches for antibody evaluation include:
Adenovirus vectors are particularly effective at stimulating T-cell responses because antigen expression occurs within host cells and promotes antigen presentation.
Evaluation of cellular immunity commonly includes:
Recombinant adenovirus vectors have been explored for vaccines against multiple pathogens.
| Target | Adenovirus Platform | Research Application |
| Coronavirus | Ad5, Ad26, ChAd | Antigen delivery and immune protection |
| Ebola virus | Ad26, ChAd | Glycoprotein vaccine development |
| Influenza virus | Ad5 and modified vectors | Broad immune response studies |
| HIV | Adenovirus vectors | Cellular immunity research |
Beyond infectious diseases, adenovirus vectors are being investigated as platforms for cancer immunotherapy. By delivering tumor-associated antigens, engineered adenoviruses can stimulate immune recognition of cancer cells.
Potential applications include:
Many individuals have antibodies against common adenovirus serotypes, particularly Ad5. Existing immunity may reduce vector uptake and limit vaccine-induced immune responses.
Alternative adenovirus serotypes, including Ad26 and chimpanzee adenovirus vectors, are being investigated to overcome this challenge.
Improving adenovirus vaccine performance requires optimization of multiple factors, including:
Balancing immune activation, safety, and manufacturing efficiency remains an important focus of current research.
Reliable analytical methods are essential for evaluating adenovirus vaccine candidates. Key research areas include:
Adenovirus vaccines represent two complementary areas of vaccine research: vaccines designed to prevent adenovirus infection itself and recombinant adenovirus platforms used for delivering antigens against other diseases.
Traditional Ad4 and Ad7 live attenuated vaccines remain important tools for controlling adenovirus-associated respiratory infections, while adenovirus vector technologies continue to expand opportunities in infectious disease vaccines and cancer immunotherapy.
As adenovirus vaccine platforms continue to evolve, comprehensive characterization and immune evaluation strategies remain essential for advancing vaccine research and development.
| Cat. No. | Product Name | Species Reactivity | Detection Sample | |
| DEIA309 | Anti-ADV IgG ELISA Kit | Human | Serum, plasma | Inquiry |
| DEIA1383G | Anti-ADV IgG ELISA Kit | Human | Serum, plasma | Inquiry |
| DEIA1383 | Anti-ADV IgA ELISA Kit | Human | Serum or plasma | Inquiry |
| DEIA310 | Anti-ADV IgA ELISA Kit | Human | Serum, plasma | Inquiry |
| DEIA311 | Anti-ADV IgM ELISA Kit | Human | Serum, plasma | Inquiry |
| DEIA1767 | Anti-ADV IgM ELISA Kit | Human | Serum, plasma | Inquiry |
| DEIA2094 | ADV-FLandK87 EcoELISA Kit | Mouse | Serum | Inquiry |
| DEIA2435 | ADV (Fecal) ELISA Kit | N/A | Stool | Inquiry |
| DEIAFY103 | ADV Hexon Antigen ELISA Kit | N/A | Feces | Inquiry |
| DEIASL108 | ADV FL ELISA Kit | Mouse | Serum | Inquiry |
| DEIASL109 | ADV K87 ELISA Kit | Mouse | Serum | Inquiry |
Loading ......
